Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Siga Technologies Inc (SIGA) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 142,220
  • Shares Outstanding, K 54,280
  • Annual Sales, $ 8,180 K
  • Annual Income, $ -39,450 K
  • 36-Month Beta 1.24
  • Price/Sales 19.19
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.9000 +71.05%
on 11/04/16
3.3400 -2.69%
on 12/02/16
+1.0400 (+47.06%)
since 11/02/16
3-Month
1.9000 +71.05%
on 11/04/16
3.3400 -2.69%
on 12/02/16
+0.7100 (+27.95%)
since 09/02/16
52-Week
0.2000 +1,525.00%
on 12/24/15
3.3400 -2.69%
on 12/02/16
+2.6300 (+424.19%)
since 12/02/15

Most Recent Stories

More News
PharmAthene Declares $2.91 Special Cash Dividend on Common Stock

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that its Board of Directors has declared a special one-time cash dividend of...

PharmAthene Receives Final Payment from SIGA of $83.9 Million

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today received a final payment from SIGA Technologies, Inc. of $83.9 million which fully satisfies...

PharmAthene Reports Third Quarter 2016 Financial and Operational Results

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the third quarter of 2016.

SIGA Announces Commencement of Rights Offering

SIGA Technologies, Inc. ("SIGA" or the "Company") (OTCMKTS:SIGA) today announced that it has commenced a rights offering (the "Rights Offering") for approximate gross proceeds of $35,000,000....

SIGA Announces Dr. Phil Gomez Joins Company as New CEO, Dr. Eric Rose to Serve as Executive Chairman of the Board

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA) today announced that Dr. Phil Gomez has been appointed the company's new Chief Executive Officer. Current CEO Dr. Eric Rose will become Executive...

SIGA Announces Oct. 12 Record Date for Rights Offering

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA) today announced that the Record Date for the Company's previously announced proposed rights offering (the "Rights Offering") is October 12th,...

SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA),SIGA Technologies, Inc., a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, announced...

PharmAthene Announces Receipt of Payments from SIGA

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90...

SIGA Announces Completion of Enrollment and Dosing in the Final Cohort of Phase III Study of TPOXX(TM) (tecovirimat)

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced completion...

SIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX(TM) (tecovirimat)

--Actions Achieve Critical BARDA Milestone; Company Now Eligible for $20.5 Million Payment

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Support & Resistance

2nd Resistance Point 3.6567
1st Resistance Point 3.4533
Last Price 3.2500
1st Support Level 2.9333
2nd Support Level 2.6167

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.